[{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"LSD1 allosteric","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/ Oscotec"},{"orgOrder":0,"company":"Beactica","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ Dong-A ST","highestDevelopmentStatusID":"2","companyTruncated":"Beactica \/ Dong-A ST"},{"orgOrder":0,"company":"Beactica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BEA-17","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ Not Applicable"},{"orgOrder":0,"company":"Beactica","sponsor":"Oscotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Termination","leadProduct":"BEA-17","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Beactica \/ Oscotec","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ Oscotec"},{"orgOrder":0,"company":"Beactica","sponsor":"National Center for Advancing Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"YAP\u2013TEAD","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beactica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Beactica \/ National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Beactica \/ National Center for Advancing Translational Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by Beactica

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Lead Product(s) : YAP–TEAD

                          Therapeutic Area : Oncology

                          Study Phase : Preclinical

                          Sponsor : National Center for Advancing Translational Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          Details : Under the collaboration, NCATS will gain access to proprietary novel proteolysis-targeting degraders of TEAD, including YAP–TEAD, from Beactica to evaluate their efficacy in disease-relevant preclinical models for treatment of cancer.

                          Brand Name : YAP–TEAD

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 26, 2023

                          Lead Product(s) : YAP–TEAD

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : National Center for Advancing Translational Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the agreement, Beactica Therapeutics will retain full exclusive global rights for further development and commercialization of the LSD1 programme, including BEA-17, a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and...

                          Brand Name : BEA-17

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 04, 2023

                          Lead Product(s) : BEA-17

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Oscotec

                          Deal Size : $178.0 million

                          Deal Type : Termination

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BEA-17 is a first-in-class small molecule targeted degrader (non-PROTAC) of the epigenetic enzyme LSD1 and its co-factor CoREST. The compound has shown promising preclinical in vivo potentiation of immune-modulating treatments in several cancer forms.

                          Brand Name : BEA-17

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 01, 2023

                          Lead Product(s) : BEA-17

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 06, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Dong-A ST Co., Ltd.

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the agreement, Oscotec is entitled to gain exclusive global rights for further development and commercialization of Beactica's programme.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 02, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Oscotec

                          Deal Size : $17.8 million

                          Deal Type : Collaboration

                          blank